ASCO GU 2022 | The evolving treatment landscape of mHSPC and mCRPC

Axel S. Merseburger, MD, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, discusses the changes in the treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant PC (mCRPC). There has been an increase in the treatments for mHSPC and mCRPC in the last decade with PARP inhibitors (PARPi) and other novel substances. The challenge now is on how best to guide the physicians to treat the patient appropriately. Dr Merseburger mentions the Phase III trials TITAN (NCT02489318), ARASENS (NCT02799602) and PRESIDE (NCT02288247) which demonstrate the logic of treatment intensification. However, precision medicine is expected to be the future of cancer treatment, which is being investigated in trials such as PRESIDE where collection of information from circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) could aid in biomarker discovery. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.